Profile data is unavailable for this security.
About the company
Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.
- Revenue in CAD (TTM)0.00
- Net income in CAD-22.91m
- Incorporated2005
- Employees18.00
- LocationResverlogix Corp300-4820 Richard Rd SWCALGARY T3E 6L1CanadaCAN
- Phone+1 (403) 254-9252
- Fax+1 (403) 254-9252
- Websitehttps://www.resverlogix.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tokens.com Corp | 1.10m | -8.16m | 14.51m | 4.00 | -- | 0.951 | -- | 13.14 | -0.0653 | -0.0653 | 0.01 | 0.1262 | 0.0547 | -- | 5.17 | -- | -42.63 | -- | -50.94 | -- | 78.38 | -- | -779.43 | -- | -- | -- | 0.0112 | -- | -- | -- | -- | -- | -- | -- |
| Hempalta Corp | 0.00 | -3.11k | 15.25m | -- | -- | 1.65 | -- | -- | -0.00007 | -0.00007 | 0.00 | 0.1119 | 0.00 | -- | -- | -- | -0.1168 | -- | -0.1181 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 113.13 | -- | -- | -- |
| Sirona Biochem Corp | 36.35k | -2.65m | 15.39m | -- | -- | -- | -- | 423.31 | -0.0105 | -0.0105 | 0.0001 | -0.011 | 0.0492 | -- | 7.70 | -- | -358.70 | -173.09 | -- | -383.49 | -- | -- | -7,297.85 | -1,405.28 | -- | -9.04 | -- | -- | -94.82 | -51.37 | 28.52 | -- | -- | -- |
| Avricore Health Inc | 3.11m | -1.01m | 15.48m | -- | -- | 8.55 | -- | 4.98 | -0.0101 | -0.0101 | 0.0313 | 0.0181 | 1.36 | -- | 7.56 | -- | -43.90 | -132.19 | -56.53 | -219.49 | 28.02 | 26.28 | -32.36 | -460.06 | -- | -59.16 | 0.0217 | -- | 1,339.92 | 26.88 | 52.10 | -- | 216.40 | -- |
| Antibe Therapeutics Inc | 0.00 | -18.24m | 15.64m | 11.00 | -- | 0.599 | -- | -- | -0.3466 | -0.3525 | 0.00 | 0.4925 | 0.00 | -- | -- | 0.00 | -28.04 | -41.95 | -29.31 | -46.17 | -- | -- | -- | -349.76 | -- | -- | 0.00 | -- | -- | -- | 23.60 | -- | -29.21 | -- |
| Resverlogix Corp | 0.00 | -22.91m | 16.47m | 18.00 | -- | -- | -- | -- | -0.085 | -0.085 | 0.00 | -0.3742 | 0.00 | -- | -- | 0.00 | -228.80 | -- | -- | -- | -- | -- | -- | -- | 0.0081 | -0.5027 | -- | -- | -- | -- | -363.74 | -- | -- | -- |
| Kane Biotech Inc | 148.98k | -4.56m | 17.14m | -- | -- | -- | -- | 115.05 | -0.0359 | -0.0396 | 0.0012 | -0.0801 | 0.0264 | 0.0779 | 0.9169 | -- | -80.74 | -77.89 | -- | -- | 73.48 | 43.27 | -3,062.39 | -241.85 | 0.3188 | -2.78 | 10.99 | -- | -94.42 | -20.26 | -17.29 | -- | -19.41 | -- |
| Cytophage Technologies Ltd | 0.00 | -4.64m | 17.20m | -- | -- | 7.25 | -- | -- | -0.5489 | -0.5489 | 0.00 | 0.0442 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -165.33 | 0.8283 | -- | -- | -- | -25.88 | -- | -- | -- |
